252 related articles for article (PubMed ID: 21264861)
1. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.
Sugauchi F; Tanaka Y; Kusumoto S; Matsuura K; Sugiyama M; Kurbanov F; Ueda R; Mizokami M
J Med Virol; 2011 Mar; 83(3):412-8. PubMed ID: 21264861
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
[TBL] [Abstract][Full Text] [Related]
3. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
[TBL] [Abstract][Full Text] [Related]
5. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
Hui CK; Cheung WW; Zhang HY; Au WY; Yueng YH; Leung AY; Leung N; Luk JM; Lie AK; Kwong YL; Liang R; Lau GK
Gastroenterology; 2006 Jul; 131(1):59-68. PubMed ID: 16831590
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
[TBL] [Abstract][Full Text] [Related]
10. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.
Viganò M; Vener C; Lampertico P; Annaloro C; Pichoud C; Zoulim F; Facchetti F; Poli F; Scalamogna M; Deliliers GL; Colombo M
Bone Marrow Transplant; 2011 Jan; 46(1):125-31. PubMed ID: 20383209
[TBL] [Abstract][Full Text] [Related]
11. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.
Miyagawa M; Minami M; Fujii K; Sendo R; Mori K; Shimizu D; Nakajima T; Yasui K; Itoh Y; Taniwaki M; Okanoue T; Yoshikawa T
J Med Virol; 2008 Dec; 80(12):2069-78. PubMed ID: 19040281
[TBL] [Abstract][Full Text] [Related]
13. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region.
Kitano K; Kobayashi H; Hanamura M; Furuta K; Ueno M; Rokuhara A; Tanaka E; Umemura T; Kiyosawa K
Eur J Haematol; 2006 Sep; 77(3):255-8. PubMed ID: 16923112
[TBL] [Abstract][Full Text] [Related]
14. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y
World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819
[TBL] [Abstract][Full Text] [Related]
15. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients.
Matsue K; Aoki T; Odawara J; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuch M
Eur J Haematol; 2009 Oct; 83(4):357-64. PubMed ID: 19508685
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
17. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.
Tamori A; Hino M; Kawamura E; Fujii H; Uchida-Kobayashi S; Morikawa H; Nakamae H; Enomoto M; Murakami Y; Kawada N
J Gastroenterol Hepatol; 2014 Sep; 29(9):1715-21. PubMed ID: 24730465
[TBL] [Abstract][Full Text] [Related]
18. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
19. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
